



**CURRICULUM VITAE ABREVIADO (CVA)**

**IMPORTANT – The Curriculum Vitae cannot exceed 4 pages. Instructions to fill this document are available in the website.**

**Part A. PERSONAL INFORMATION \***

First name	LAURA		
Family name	ORÍO		
Gender (*)	female		
Social Security, Passport, ID number			
e-mail	<a href="mailto:lorio@psi.ucm.es">lorio@psi.ucm.es</a>	URL Web	<a href="https://www.ucm.es/lauraorio">https://www.ucm.es/lauraorio</a>
Open Researcher and Contributor ID (ORCID) (*)	0000-0002-9614-4062		

(\*) *Mandatory*

**A.1. Current position**

Position	FULL PROFESSOR of Psychobiology		
Initial date	6th June 2025		
Institution	COMPLUTENSE UNIVERSITY OF MADRID		
Department/Center	PSYCHOBIOLOGY AND BEHAVIORAL SCIENCE METHODS	FACULTY OF PSYCHOLOGY (UCM)	
Country	SPAIN	Teleph. number	913943074
Key words	Neuropsychopharmacology, microbiota-gut-brain axis, neuroinflammation, alcohol use disorder, binge drinking, wernicke-korsakoff syndrome, , apolipoproteins, cognitive decline		

**A.2. Previous positions (research activity interruptions, indicate total months)**

Period	Position/Institution/Country/Interruption cause
21/02/2020 – 05/06/2025	PROFESORA TITULAR, UCM, Madrid
01/12/2015 - 20/02/2020	PROFESORA CONTRATADA DOCTORA, UCM, Madrid
24/10/2010 - 30/11/2015	PROFESORA AYUDANTE DOCTORA, UCM, Madrid
23/10/2009 - 24/10/2011	PROFESORA TITULAR INTERINA, UCM, Madrid
15/01/2009 - 14/07/2010	POSTDOCTORAL RESEARCHER at FIMABIS, Málaga
01/11/2006 -29/11/2008	FULBRIGHT POSTDOCTORAL RESEARCHER at SRIPPS RESEARCH INST., La Jolla, Ca, EE.UU.
01/01/2002 - 31/12/2005	FPU PREDOCTORAL RESEARCHER, UCM, Madrid

\*Maternity leaves (two 6-months periods in 2010 and 2014)

**A.3. Education**

PhD, Licensed, Graduate	University/Country	Year
PhD in Pharmacology (awarded)	COMPLUTENSE UNIVERSITY MADRID	14th/10/2005
Bachelor of Pharmacy	SALAMANCA UNIVERSITY	2001

**Part B. CV SUMMARY (max. 5000 characters, including spaces)**

Number of six-years research terms (*sexenios de investigación*): 3: [2002-2007], [2008-2013] and [2014-2019]. The 4<sup>th</sup> (2020-2025) is currently being processed]

Author of > **60 international publications indexed in JCR**, 83% of them ubicated in Q1 of their categories, including some D1 publications (*British Journal of Pharmacology; Neuropsychopharmacology; Int J Neuropsychopharmacology*) and preferent (1st/last/corresponding) author in more than a half of them. 6 contributions in book chapters and >130 communication to scientific meetings. H index= 24. More than 1600 citations (WOS).

My professional career was dedicated to the study of the effects of drugs of abuse with emphasis in their neuroinflammatory effects. In my predoctoral stage (2002-2005; Fac. Medicine, UCM, Madrid)

I studied the neuroinflammatory effects of MDMA, a pioneer study about neuroinflammation and ecstasy (selected publication **Orio et al., J. of Neurochemistry, 2005**) which was awarded (**Premio Extraordinario de Doctorado**). I obtained a **Fulbright award** to do my postdoc at **The Scripps Research Institute (2006-2008; La Jolla, USA)** in the Koob's lab, an internationally-recognized scientist and actual director of NIAAA. I worked in my own Fulbright project (**Orio et al. 2009 J of Neurosci**, demonstrating for the first time an involvement of the endocannabinoid system in sophisticated models of cocaine addiction) and in Koob's projects (selected public **Orio et al., 2010 Addiction Biol**). I came back to Spain as a part of an **European Project** of the FPVII European Commission at the FIMABIS (Málaga), which resulted in my first **patent registration** (<https://patents.google.com/patent/WO2012101292A1/es>). In the same year (2009) I obtained a position at UCM (Fac. Psychology) and started my independent research. I obtained my first grant as PI in 2010 and since then I have been funded up to date. I was promoted to Associate Professor (Profesor Titular) by **International merits based on Crown Indicator**. **Currently, I am Full Professor of Psychobiology at UCM (2025)**. My main line of research during these years have focused on the study of the microbiome-gut-brain axis and neuroinflammation in alcohol abuse and related pathologies. Derived of this research (grant PNSD) is the discovery of the antiinflammatory, antioxidant, neuroprotectant and antidepressant actions of OEA preventing effects of the alcohol binge drinking (**Antón et al., 2017, Addiction Biology, 95 citations**), which was **awarded by the International Drugs of Abuse Society (IDARS award 2015, Australia)** and I led the registration of an **international patent** <https://patents.google.com/patent/WO2017178682A1/es>. We studied also the specific mechanism of action of OEA protecting the gut-brain axis (**Antón et al., 2018b, British Journal of Pharmacology, D1**). In the past years I made an effort to integrate different disciplines to my research, including mainly Pharmacology (first academic formation), Psychobiology (since postdoctoral training up to date) and Neuroscience, but also Microbiology, Clinical Psychology, etc. I am the actual **Director of research groups at the UCM** (<https://www.ucm.es/grupos/grupo/566>) and **at the Instituto the Investigación sanitaria Hospital 12 de octubre, Madrid** (<https://imas12.es/investigacion/neurociencia/>), combining preclinical studies in animal models and clinical research in humans (binge drinkers, AUD patients, Wernicke's, etc.) (**Escudero et al., 2023 Int J Neuropsychopharm, 2024a Int J Neuropsychopharm, 2024b Addict Behav**). I recently become part of the **Spanish Network in Addiction, as PI of my own research group (RD24/0003/0010), a prestigious ISCIII network for cooperative research in health** (Riapad, [Red de Investigación en atención primaria de adicciones](#)).

I have recruited FPU and FPI students previously and many master students. Indeed, I have directed more than 35 experimental TFMs and **8 Doctoral Thesis**. I am **former Director of Master in Psychopharmacology and drugs of abuse (UCM)** for 6 years (2014-2020) and a member of the **Research Committee** of the Faculty, member of the UCM **Commmitee on Animal Research and Ethics (CEEA)** for more than 10 years. I am currently part of the Spanish STATE INVESTIGATION AGENCY (A.E.I), as manager of the Psychology area (**[Colaboradora de la División de Coordinación, Evaluación y Seguimiento Científico y Técnico.;](#)**) and evaluator for other **international research agencies** (FonCYT (Argentina), FnrS (Belgium); ANII (Uruguay) and also national (AEI) and autionomic (Aqu Catalunya, UPV/EHU, Junta de Andalucía) research agencies. I participate in the *peer review* process of >25 different journals and I am **Assistant Editor** of journals such as Biomedicine and Frontiers (Neuropharmacology section); member of the **Directive of Socidrogalcohol** or **Scientific Advisor** for pharmaceutical companies (i.e. Galea Theapeutics).

## **Part C. RELEVANT MERITS** (sorted by typology)

### **C.1. Publications** (see instructions)

1. Escudero, B., López-Valencia, L., Arias Horcajadas, F., & **Orio, L\***. (4/4). Divergent Roles of APOAI and APOM in the Identification of Alcohol Use Disorder and their Association with Inflammation and Cognitive Decline: A Pilot Study. **The International Journal of Neuropsychopharmacology**, (2024) 27(7): pyae029. **\*corresponding author** [Q1](#)
2. Escudero, B., Arias Horcajadas, F., & **Orio, L\***. (3/3). Changes of attentional bias in patients with alcohol use disorder during abstinence: A longitudinal study. **Addictive Behaviors**, (2024) 157, 108098. [Q1](#) **\*corresponding author**
3. López-Valencia, L; Moya, M; Escudero, B; García-Bueno, B; **Orio, L\*** (5/5) Bacterial lipopolysaccharide forms aggregates with apolipoproteins in male and female rat brains after ethanol binges. **Journal of Lipid Research** (2024) 6(3): 100509 **\*corresponding author** [Q1](#)
4. Escudero, B; Moya, M; López-Valencia, L; Arias, F; **Orio, L\*** (5/5) Reelin plasma levels identify cognitive decline in Alcohol Use Disorder subjects during early abstinence: the influence of APOE4 expression". **International Journal of Neuropsychopharmacology** (2023) 26(8):545-556 **\*corresponding author** [Q1](#)
5. **Orio L\***, Arias F, Escudero B (1/3) A case of Wernicke's Encephalopathy that maintains long-term cognitive deterioration but not inflammation in spite of thiamine supplementation. **Psychiatry & Clinical Neurosciences** (2022) 76: 475-478 **\*corresponding author**. [Q1](#) (IF=12.1)
6. Moya M, San Felipe D, Ballesta A, Alén F, Rodríguez de Fonseca F, García-Bueno B, Marco EM, **Orio L\*** (8/8). Cerebellar and cortical TLR4 activation and behavioral impairments in Wernicke-Korsakoff Syndrome: Pharmacological effects of oleoylethanolamide. **Prog Neuropsychopharmacol Biol Psychiatry** (2021) 108:110190 **\*corresponding author**. [Q1](#)
7. Rodríguez-González A, Vitali F, Moya M, De Filippo C, Passani MB, **Orio L\*** (6/6). Effects of Alcohol Binge Drinking and Oleoylethanolamide Pretreatment in the Gut Microbiota. **Front Cell Infect Microbiol**. (2021) 11:731910 **\*corresponding author** [Q1](#)
8. Antón M, Rodríguez-González A, Rodríguez-Rojo IC, et al., **Orio L\*** (11/11). Increased plasma oleoylethanolamide and palmitoleoylethanolamide levels correlate with inflammatory changes in alcohol binge drinkers: the case of HMGB1 in women. **Addiction Biology** (2018) **\*corresponding author**. [Q1](#)
9. **Orio L\***, Antón M, Rodríguez-Rojo IC, et al., Cadaveira F (1/10). Young alcohol binge drinkers show alterations in the immune/inflammatory response with higher susceptibility of women: implications for neuropsychological abilities. **Addiction Biology** (2018) **\*corresponding author**. [Q1](#)
10. Anton M, Rodriguez-Gonzalez A, Ballesta A, et al., **Orio L\*** (11/11). Alcohol binge disrupts the rat intestinal barrier: the partial protective role of oleoylethanolamide. **British Journal of Pharmacology** (2018) 175:4464-4479. **\*corresponding author** [Q1](#) (D1)

**C.2. Congress**, indicating the modality of their participation (invited conference, oral presentation, poster)

I have been **presenting author** in **meetings** organized by **international societies** (European Foundation for Alcohol Research-ERAB, International Meeting on Alcohol and Global Health; Scientific Meeting of the Research-Society-on-Alcoholism, Society for Neuroscience-SfN; LisbonAddictions; Asia-Pacific Society for Alcohol Abuse Research-APSAAR; European Congress of Psychiatry-EPA; Alcoholism and Stress: A Framework for Future Treatment Strategies; International Symposium on Public Health; World Congress on Public Health and Nutrition-OMICS International; European Brain Injury Consortium- World Congress on brain injury; International Drug Abuse Research Society-IDARS, European Society for Brain Research in Alcoholism, etc.) and national societies.

**C.3. Research projects**, indicating your personal contribution. In the case of young researchers, indicate lines of research for which they have been responsible.

- Title:** Atención primaria, cronicidad y promoción de la salud. Red de Investigación en atención primaria y salud (RIAPAD). **ISCHII:** Redes de Investigación Cooperativa Orientadas a resultados en salud. Ref: **RD24/0003/0010**. **PI: L.Orio**. Date: 01/01/2025 a 31/12/2027 Budget: 104.060 €
- Title:** Bacterial toxin detoxification system in the central nervous system and periphery in alcohol abuse and schizoprenia: role of lipoproteins (LIPOAID). **MICINN(PGC2021)** Ref: **PID2021-127256OB-I00**. **PI: L.Orio**. Date: 2022-2026. Budget: 145.200 €
- Title:** Signaling of bacterial products and neuroimmune alterations in alcohol abuse-induced neuropsychological impairment **MICINN** [RTI2018-099535-B-100]. **PI: L.Orio**. Date: 2019-2021. Budget: 90.750,00 €
- Title:** Medical complications of alcohol use disorders. **ISCHII (RETICS: Red de Trastornos Adictivos)** [Ref: RD16/0017/0021]. **PI: MI Colado**. Date: 2017 a 2021 Budget: 236.126,00 €. Team member.
- Title:** Activación del sistema inmune innato en el síndrome de Wernicke-Korsakoff (INWERKOFF). **UCM-SANTANDER** [Ref. **PR26/16-11B-1**]. **PI:L.Orio (coord.)/B.García-Bueno/E. Marco**. Date: 2017-2018 Budget: 30.000 €. **PI and coordinator**.
- Title:** Consumo abusivo de alcohol: prevención del daño y mecanismos neuroprotectores por oleoiletanolamida y derivados. **MSPSI-PNSD:** Ministerio de Sanidad y Política Social e Igualdad, Plan Nacional sobre drogas [ref. 2015/005]. **PI: L.Orio**. Date: 2016-2018. Budget: 106.058,00 €
- Title:** Macrófagos perivasculares en el sistema nervioso central como diana para el desarrollo de nuevas estrategias terapéuticas frente a la depresión. **MECC:** Ministerio de Economía y Competitividad [SAF-2012-38123].**PI: B. García-Bueno**. Date: 2013-2015 Budget: 89.000 €: Team member,
- Title:** Red de Trastornos Adictivos. **ISCHII (Programa RETICS) [RD12/0028/0021]**. **PI: Eva Mª Marco López**. Date: 2016-2017 Cuantía subvención: 91.500 €: Team member.
- Title:** Complicaciones derivadas del consumo de alcohol y cocaína: un enfoque en neuroinflamación. **MSPSI-PNSD** [ref.2011/005]. **PI: L.Orio**. Date: 2011-2014. Budget: 59.879 €

**C.4. Contracts, technological or transfer merits**, Include patents and other industrial or intellectual property activities (contracts, licenses, agreements, etc.) in which you have collaborated. Indicate: a) the order of signature of authors; b) reference; c) title; d) priority countries; e) date; f) Entity and companies that exploit the patent or similar information, if any.

**Patent 2:** Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol.  
Inventors: **L. Orío**, M.Antón, F.R de Fonseca. N°: P201630447 Priority date and country: 11/04/2016. Grant date in Spain: 12/09/2018. International protection, Patent Cooperation Treaty [PCT/ES2017/070225]. Date: 11/04/2017. Licensed to EINSOF BIOHEALTH™ (Florida, U.S.A.).

**Patent 1:** Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido GLP-1. Inventors: F. Rodríguez de Fonseca, M. Romero, **L. Orío Ortiz**, JM Decara, M. Alonso. N°: P201030093. Priority date in Spain: 26/01/2010 PCT/ES2011/070042 Internacional PCT (Patent Cooperation Treaty: 25/01/2011). Licensed to Vivia Biotech S.L^

**Art. 60 contracts:** (2) “Efectos del nutraceutico LIVERMAX Duo en pacientes con Trastorno por Uso de Alcohol”. **Aora Life, S.L.** Date: 2026-2028. Budget:: 45.500 €; (1). **PI: L.Orio**

**FPVII European Commission. 7<sup>th</sup> Framework program.**[ID: FP7-Health-2007-B]. Title: Search For New Therapeutic Agents Against Complicated Obesity By Reprofiling Existing Drugs. IP: F. R. de Fonseca. Date: 2009-2011. Budget: 594.000 €. Goal: creation of the pharmaceutical company ViviaBiotech, S.L. Postdoctoral researcher.